Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
Senthil Damodaran, Fengmin Zhao, Dustin A. Deming, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 14, pp. 1552-1561
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Antonino Glaviano, Aaron Song Chuan Foo, Hiu Yan Lam, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 737
The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
Lingyu Tian, Daniel J. Smit, Manfred Jücker
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2652-2652
Open Access | Times Cited: 123
The NCI-MATCH trial: lessons for precision oncology
Peter J. O’Dwyer, Robert J. Gray, Keith T. Flaherty, et al.
Nature Medicine (2023) Vol. 29, Iss. 6, pp. 1349-1357
Closed Access | Times Cited: 84
The emerging role of PI3K inhibitors for solid tumour treatment and beyond
Carmen Belli, Matteo Repetto, Santosh Anand, et al.
British Journal of Cancer (2023) Vol. 128, Iss. 12, pp. 2150-2162
Open Access | Times Cited: 46
PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
Premila D. Leiphrakpam, Chandrakanth Are
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3178-3178
Open Access | Times Cited: 46
PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities
Xiaohong Liu, Wuxuan Mei, Pengfei Zhang, et al.
Pharmacological Research (2024) Vol. 202, pp. 107123-107123
Open Access | Times Cited: 18
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Jiaojiao Zheng, Siying Wang, Lei Xia, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access | Times Cited: 4
Novel clinical trial designs emerging from the molecular reclassification of cancer
Mina Nikanjam, Shumei Kato, Teresa Allen, et al.
CA A Cancer Journal for Clinicians (2025)
Open Access | Times Cited: 3
Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents
Maria Antonietta Occhiuzzi, Gernando Lico, Giuseppina Ioele, et al.
European Journal of Medicinal Chemistry (2022) Vol. 246, pp. 114971-114971
Closed Access | Times Cited: 42
Precision Oncology: Evolving Clinical Trials across Tumor Types
I-Wen Song, Henry Hiep Vo, Ying‐Shiuan Chen, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 1967-1967
Open Access | Times Cited: 37
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Funda Meric‐Bernstam, James M. Ford, Peter J. O’Dwyer, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 8, pp. 1412-1422
Open Access | Times Cited: 36
Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma
Jieun Bang, Mihyeon Jun, S. J. Lee, et al.
Pharmaceutics (2023) Vol. 15, Iss. 8, pp. 2130-2130
Open Access | Times Cited: 27
Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment
Fabio Raith, Daniel H. O’Donovan, Clara Lemos, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2289-2289
Open Access | Times Cited: 23
Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers
Khine Shan, Amalia Bonano-Rios, Nyein Wint Yee Theik, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 1973-1973
Open Access | Times Cited: 11
Targeted Treatment against Cancer Stem Cells in Colorectal Cancer
Julia Martínez-Pérez, C. Sevillano, Maria A Dominguez-Cejudo, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 6220-6220
Open Access | Times Cited: 10
CAR-T therapy and targeted treatments: Emerging combination strategies in solid tumors
Jiahao Liu, Xiaofei Jiao, Ding Ma, et al.
Med (2024) Vol. 5, Iss. 6, pp. 530-549
Closed Access | Times Cited: 7
Recent advances in the understanding and management of liposarcoma
Candace L. Haddox, Richard F. Riedel
Faculty Reviews (2021) Vol. 10
Open Access | Times Cited: 35
Genetic Heterogeneity and Tissue-specific Patterns of Tumors with MultiplePIK3CAMutations
Smruthy Sivakumar, Dexter X. Jin, Ruchita Rathod, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 6, pp. 1125-1136
Open Access | Times Cited: 15
Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)
Xueqin Huang, Li You, Eugenie Nepovimová, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 15
Heterogeneity in precision oncology
Bartłomiej Tomasik, Filip Garbicz, Marcin Braun, et al.
Cambridge Prisms Precision Medicine (2023), pp. 1-37
Open Access | Times Cited: 11
Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1
Jun Gong, Alain C. Mita, Zihan Wei, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 4
Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy
Thomas N. O’Connor, Emily Schultz, Jianxin Wang, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1749-1749
Open Access | Times Cited: 4
Durable disease regression with copanlisib treatment in PI3K-mutated metastasizing ameloblastoma: A case report
Meghan M Lynch, Pedro Hermida-Viveiros, Sean Stencel, et al.
Rare Tumors (2025) Vol. 17
Open Access
Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting
Pedram Yadollahi, Kelli A. McCord, Yong Li, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H
Mohamed A. Gouda, Zihan Wei, Jordi Rodón, et al.
JCO Precision Oncology (2025), Iss. 9
Closed Access
Page 1 - Next Page

Scroll to top